Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Tanum

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Addiction Science & Clinical Practice|July 19, 2022
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative studyAnne Marciuch, Ida Halvorsen Brenna, Bente Weimand, et al.
BMC Pharmacology & Toxicology|April 29, 2016
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli, et al.
Journal of Affective Disorders|November 1, 2015
Speed of recovery from disorientation may predict the treatment outcome of electroconvulsive therapy (ECT) in elderly patients with major depressionTor Magne Bjølseth, Knut Engedal, Jūratė Šaltytė Benth, et al.
Addiction (Abingdon, England)|December 18, 2020
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexoneKristin Klemmetsby Solli, Arild Opheim, Zill-E-Huma Latif, et al.
Drug and Alcohol Dependence|October 16, 2025
Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment periodChristina L Redondo, Bente Weimand, Jūratė Šaltytė Benth, et al.
European Addiction Research|September 27, 2021
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and RelapseZhanna Gaulen, Ida Halvorsen Brenna, Lars Thore Fadnes, et al.
Medicine|January 3, 2020
Enabling patients to cope with psychotropic medication in mental health care: Evaluation and reports of the new inventory MedSupportKarin Drivenes, John-Kåre Vederhus, Vegard Øksendal Haaland, et al.
Contemporary Clinical Trials|October 21, 2023
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trialArild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.
The American Journal on Addictions|February 1, 2019
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up studyZill-E-Huma Latif, Kristin K Solli, Arild Opheim, et al.
European Addiction Research|November 4, 2024
Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic StudyIda Halvorsen Brenna, Karin Merethe Waleur, Jūratė Šaltytė Benth, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Addiction Science & Clinical Practice|July 19, 2022
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative studyAnne Marciuch, Ida Halvorsen Brenna, Bente Weimand, et al.
BMC Pharmacology & Toxicology|April 29, 2016
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli, et al.
Journal of Affective Disorders|November 1, 2015
Speed of recovery from disorientation may predict the treatment outcome of electroconvulsive therapy (ECT) in elderly patients with major depressionTor Magne Bjølseth, Knut Engedal, Jūratė Šaltytė Benth, et al.
Addiction (Abingdon, England)|December 18, 2020
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexoneKristin Klemmetsby Solli, Arild Opheim, Zill-E-Huma Latif, et al.
Drug and Alcohol Dependence|October 16, 2025
Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment periodChristina L Redondo, Bente Weimand, Jūratė Šaltytė Benth, et al.
European Addiction Research|September 27, 2021
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and RelapseZhanna Gaulen, Ida Halvorsen Brenna, Lars Thore Fadnes, et al.
Medicine|January 3, 2020
Enabling patients to cope with psychotropic medication in mental health care: Evaluation and reports of the new inventory MedSupportKarin Drivenes, John-Kåre Vederhus, Vegard Øksendal Haaland, et al.
Contemporary Clinical Trials|October 21, 2023
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trialArild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.
The American Journal on Addictions|February 1, 2019
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up studyZill-E-Huma Latif, Kristin K Solli, Arild Opheim, et al.
European Addiction Research|November 4, 2024
Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic StudyIda Halvorsen Brenna, Karin Merethe Waleur, Jūratė Šaltytė Benth, et al.
Pageof 6